Free Trial
NASDAQ:FBRX

Forte Biosciences Q4 2023 Earnings Report

Forte Biosciences logo
$12.76 -1.90 (-12.96%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$12.71 -0.05 (-0.36%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences EPS Results

Actual EPS
-$0.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Forte Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Forte Biosciences Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 18, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Forte Biosciences' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Forte Biosciences Earnings Headlines

A grave, grave error.
It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been crippled. Japan’s in the process of being crippled. And it seems Europe may be next. And despite the president insisting that the Fed reduce rates – and with Vice President J.D. Vance saying “the refusal by the Fed to cut rates is monetary malpractice” – the Fed has decided to hold rates steady once again.
TD Cowen Remains a Buy on Forte Biosciences (FBRX)
Forte Biosciences price target lowered to $61 from $64 at Chardan
See More Forte Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email.

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

View Forte Biosciences Profile

More Earnings Resources from MarketBeat